Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

ARTL
Artelo Biosciences, Inc.US flagNASDAQ Capital Market
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Gregory D. Gorgas M.B.A.
Full Time Employees
5
Sector
Healthcare
Industry
Biotechnology
Address
505 Lomas Santa Fe Solana Beach CA United States of America 92075
IPO Date
Jun 21, 2019
Similar Companies
Business
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Company News

  • Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

  • Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

  • Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

  • Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

  • Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

  • Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

  • Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

  • Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

  • Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

  • Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

  • Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

  • Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

  • Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

  • Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

  • Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

  • Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

  • Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

  • Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

  • Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

  • Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy